With a rising incidence of over 20 million affected people in the United States alone, dry eye disease (DED) is now considered a major ocular condition. DED affects patients of all ages and has been shown to negatively impact a patient’s quality of life both physically and psychologically. Increased awareness has led to significant worldwide progress in research, but dry eye management can be frustrating for both patients and clinicians alike. Significant strides have been made in not only defining and classifying DED, but also understanding the association between the condition, systemic comorbidities and systemic medications. The focus of this article will be iatrogenic DED; specifically, dry eye induced by systemic medications. Read More